Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off

Upshaw JN, Ruthazer R, Miller KD, Parsons SK, Erban JK, O'Neill AM, Demissei B, Sledge G, Wagner L, Ky B, Kent DM. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. Clin Breast Cancer. 2019 Aug;19(4):259-267.e1. doi: 10.1016/j.clbc.2019.04.012. Epub 2019 May 2. PubMed PMID: 31175052; PubMed Central PMCID: PMC6667295